RxDoctor Payments Data

Sarah Stamm

Physician Assistant · Lewes, DENPI 1851765333

Payments from drug & device makers

$795in general payments, 2019–2025

Across 13 payments — averaging $61.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$233
  • Avanir Pharmaceuticals, Inc.$122
  • Biohaven Pharmaceuticals, Inc.$115
  • Heartflow, Inc.$113
  • Silk Road Medical, Inc.$102
  • Amarin Pharma, Inc.$28
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$795100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$795 in reported general payments places this provider in the 70th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$104,611
Medicare patients
475
Services billed
1,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$22,079
TrulicityDulaglutide18$18,134
Breo ElliptaFluticasone/Vilanterol21$16,009
Spiriva HandihalerTiotropium Bromide16$13,308
MounjaroTirzepatide11$12,414
ShingrixVaricella-Zoster Ge/As01b/Pf45$10,009
Spiriva RespimatTiotropium Bromide11$5,191
Rosuvastatin Calcium249$3,490
Atorvastatin Calcium239$3,196
Omeprazole161$2,367
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide25$2,073
Duloxetine Hcl39$1,628
Valsartan47$1,609
Metoprolol Succinate68$1,507
Levothyroxine Sodium132$1,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$18$30,54929 claims
GSKBreo Ellipta, Shingrix$18$26,01866 claims
Novo NordiskOzempic$19$22,07919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →